Last €2.46 EUR
Change Today -0.052 / -2.07%
Volume 0.0
HQ8A On Other Exchanges
As of 2:07 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

lpath inc-class a (HQ8A) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/19/14 - €3.62
52 Week Low
12/3/14 - €1.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for LPATH INC-CLASS A (HQ8A)

Related News

No related news articles were found.

lpath inc-class a (HQ8A) Related Businessweek News

No Related Businessweek News Found

lpath inc-class a (HQ8A) Details

Lpath, Inc., a biotechnology company, focuses on the discovery and development of lipidomic-based therapeutic antibodies for treating a range of human diseases primarily in the United States. The company’s lead product candidate includes iSONEP, a monoclonal antibody against sphingosine-1-phosphate (S1P), which has completed Phase I clinical trials to treat wet age-related macular degeneration; and is in Phase 1b/2a clinical trials to treat retinal pigment epithelium detachment. Its products under development also comprise ASONEP, a systemic formulation of sonepcizumab and a mAb against the bioactive lipid S1P that is in Phase 2a clinical trials for the treatment for renal cell carcinoma; various forms of cancer; and other angiogenic-related and inflammatory-oriented indications. In addition, the company is developing Lpathomab, a mAb against lysophosphatidic acid, which is in pre-clinical trials intended for the treatment of neuropathic pain, traumatic brain injury, spinal cord injury, and fibrosis cancer. It has a collaboration agreement with Pfizer Inc. to develop and commercialize iSONEP. Lpath, Inc. is based in San Diego, California.

24 Employees
Last Reported Date: 03/18/14

lpath inc-class a (HQ8A) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $365.3K
Chief Development Officer and Senior Vice Pre...
Total Annual Compensation: $215.4K
Senior Vice President of Research
Total Annual Compensation: $215.4K
Compensation as of Fiscal Year 2013.

lpath inc-class a (HQ8A) Key Developments

Lpath Inc. - Special Call

To update on the progress of the Nexus trial as well as other programs

Lpath Announces Executive Changes

Lpath Inc. announced that Scott Pancoast has resigned as president, chief executive officer and a member of the board of directors, effective from November 3, 2014. The board of directors has appointed biotechnology consultant Michael Lack as the company's interim chief executive officer while the board conducts a search for a new CEO. Mr. Pancoast served as the president and CEO of Lpath since March 2005 and as a director of Lpath since 1998. Mr. Lack currently serves as a member of the board of directors of Immunomic Therapeutics Inc.

Lpath Mulls Acquisitions

Lpath Inc. (NasdaqCM:LPTN) is seeking acquisitions. Lpath Inc. has completed a follow-on equity offering in the amount of $12.53 million. Lpath said that it plans to raise funds via direct offering and plans to use part of proceeds for acquisitions too. Lpath said, "Lpath may also use a portion of the net proceeds to invest in or acquire businesses or technologies that it believes are complementary to its own, although it has no current plans, commitments or agreements with respect to any acquisitions as of the date hereof."


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HQ8A:GR €2.46 EUR -0.052

HQ8A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HQ8A.
View Industry Companies

Industry Analysis


Industry Average

Valuation HQ8A Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.1x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LPATH INC-CLASS A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at